Opdivo revenue also grew 10% year over year ... This is among the highest growth rates among S&P 500 REITs. VICI also announced and originated $1.8 billion in acquisitions for the year.

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...

Avi Kapoor Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo JMP Securities initiates coverage on Summit Therapeutics, citing ...

It believes ciforadenant could develop as part of a combination therapy to treat first line metastatic renal cell cancer or ...

Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Opdivo/Yervoy has been approved since 2018 as first-line treatment for patients with intermediate- and poor-risk advanced RCC, and BMS was hoping to extend the use of the regimen into patients ...

2-Year U.S. Treasury Note Continuous Contract $102.578-0.020-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.461-0.039-0.04% 10-Year U.S. Treasury Note Continuous Contract $109.391-0.031 ...

The company’s top-selling drugs include cancer therapies Revlimid and Opdivo and anticoagulant Eliquis. Bristol-Myers shares underperformed in 2023, and the company recently cut expectations for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...